The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent

Documenti analoghi

• Combination therapies augment the anti-tumor activity of agonist CD27 mAb in human CD27 transgenic mouse models
  di: He, Li-Zhen, et al.
  Pubblicazione: (2013)
• CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy
  di: Wasiuk, Anna, et al.
  Pubblicazione: (2017)
• Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
  di: Ramakrishna, Venky, et al.
  Pubblicazione: (2015)
• Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine
  di: He, Li-Zhen, et al.
  Pubblicazione: (2015)
• Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies
  di: Ansell, Stephen M., et al.
  Pubblicazione: (2020)